Payment overview · 2025
General Payments
$105.18
4 reported records · 3 companies
Healthcare provider profile · identity verified
Glenne Gunther, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LIBBY, MT · NPI 1629044276
Verified facts
What the public records show
CMS Open Payments records show Glenne Gunther, MD received $105.18 in general payments during 2025 across 4 reported records.
CSL Behring accounted for 42.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Haegarda.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Haegarda as an associated drug or biological on 3692 records involving 1703 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Haegarda by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CSL Behring | Unresolved — no canonical attribution shown | $44.88 | 42.7% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $38.86 | 37.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.44 | 20.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $105.18 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $38.86 | 1 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| Haegarda Normalized: haegarda |
Biological | CSL Behring | $21.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Haegarda haegarda |
2025 | Haegarda | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Haegarda open payments reported associated product |
CMS Open Payments — General Payments 3692 supporting records · 1703 recipient NPIs · example record 1232339032 |
Haegarda · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 389 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 349 | 82 |
| Losartan Potassium | Losartan Potassium | 320 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 64 |
| Omeprazole | Omeprazole | 256 | 72 |
| Lisinopril | Lisinopril | 174 | 46 |
| Potassium Chloride | Potassium Chloride | 169 | 39 |
| Metformin Hcl | Metformin Hcl | 168 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 151 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 146 | 22 |
| Alendronate Sodium | Alendronate Sodium | 144 | 39 |
| Gabapentin | Gabapentin | 130 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 33 |
| Eliquis | Apixaban | 125 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 26 |
| Furosemide | Furosemide | 109 | 30 |
| Lorazepam | Lorazepam | 105 | 27 |
| Jardiance | Empagliflozin | 103 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 22 |
| Simvastatin | Simvastatin | 83 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 13 |
| Fentanyl | Fentanyl | 70 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 20 |
| Tramadol Hcl | Tramadol Hcl | 63 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 14 |
| Allopurinol | Allopurinol | 59 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 15 |
| Trulicity | Dulaglutide | 51 | suppressed |
| Pregabalin | Pregabalin | 49 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 14 |
| Mirtazapine | Mirtazapine | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 48 | 19 |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | 11 |
| Celecoxib | Celecoxib | 42 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 41 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 13 |
| Ozempic | Semaglutide | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | 11 |
| Prednisone | Prednisone | 37 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Estradiol | Estradiol | 36 | 14 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Meloxicam | Meloxicam | 30 | 12 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 19 |
| Alprazolam | Alprazolam | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 16 |
| Baclofen | Baclofen | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Haegarda | C1 Esterase Inhibitor | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $105.18 · 4 records | CSL Behring | Andembry, Haegarda, INSPIRE, WATCHMAN FLX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Haegarda play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with CSL Behring?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error